Market Cap 6.58B
Revenue (ttm) 130.13M
Net Income (ttm) -260.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -200.26%
Debt to Equity Ratio 0.00
Volume 661,600
Avg Vol 606,896
Day's Range N/A - N/A
Shares Out 66.42M
Stochastic %K 48%
Beta 2.12
Analysts Strong Sell
Price Target $118.36

Company Profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid r...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 264 4280
Fax: 857 264 4299
Address:
222 Berkeley Street, 12th Floor, Boston, United States
Stonky_Mcprofitface
Stonky_Mcprofitface Oct. 4 at 8:01 AM
$RYTM Bad price?
0 · Reply
TeeMan123
TeeMan123 Oct. 2 at 6:19 PM
$RYTM stock getting pressure over PWS effectiveness… end of day do you trust Meeker sees something or not? Meeker has been super conservative about starting a trial off a whim. You have to give the man the benefit of the doubt.
1 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 12:24 AM
$RYTM: Unusual Options Activity Alerted CALL flow observed 500x contracts at Strike price of $115 Exp on 01/16/2026 with Premium of $265K and showing BEARISH Sentiment
0 · Reply
Quantumup
Quantumup Oct. 1 at 11:52 AM
Stifel⬇️ $SLNO $115 was $118/reit Buy after refreshing its PWS model to reflect recent KOL feedback—still sees pot $2B+ WW rev.. $AARD $RYTM Stifel said: Management remains confident in Vykat's safety and broader risk/benefit profile (i.e., consistent with data/label and known AE-profile), noting feedback from KOLs and patient advocacy groups is positive. Looking ahead, management remains confident in the growth trajectory of Vykat, even as naturally there's some element of a "bolus" here (2Q numbers can't be extrapolated linearly in perpetuity). EU also represents a potential meaningful expansion opportunity next year (similar prevalence numbers; if anything, more concentrated in certain countries). We are also refreshing our PWS market model to reflect our recent KOL feedback (LINK): 50% penetration within the target/addressable population (or 30% of all PWS). This very slightly lowers our estimates but still supports a substantial opportunity ($2B+ WW); our TP goes to $115 (from $118).
0 · Reply
Quantumup
Quantumup Oct. 1 at 10:32 AM
Jones Trading🏁 $AARD Buy/$33 $SLNO $RYTM Jones Trading said: We are initiating coverage of Aardvark Therapeutics (ticker: AARD) with a Buy Rating and $33 PT. Aardvark is a clinical-stage biotech company focused on treating obesity and hyperphagia (excessive eating). The core of Aardvark's portfolio is ARD-101, an oral small molecule agonist of TAS2R, which increases gut-localized secretion of satiety hormones, including GLP-1 and CCK. Jones Trading added:
0 · Reply
abcdzepeda
abcdzepeda Sep. 30 at 6:36 PM
$RYTM Dear Lord , May your favor be with us and allow for some awesome PWS Data to be released soon!  Amen!
0 · Reply
highnihilism
highnihilism Sep. 30 at 7:50 AM
$BUD Anheuser-Busch Inbev: 510 trades, $347K vs $1.08M avg (0.32x). $272K calls / $75K puts. 96% single-leg. $RYTM Rhythm Pharmaceuticals: 17 trades, $275K vs $180K avg (1.52x). $272K calls / $3K puts. 98% single-leg. $UCO ProShares Ultra Bloomberg Crude Oil: 1,063 trades, $440K vs $624K avg (0.70x). $270K calls / $171K puts. 92% single-leg. $NVT Nvent Electric: 196 trades, $311K vs $183K avg (1.70x). $269K calls / $42K puts. 91% single-leg.
0 · Reply
InvestorWisdom
InvestorWisdom Sep. 29 at 2:11 PM
$RYTM nice charts.
0 · Reply
Quantumup
Quantumup Sep. 29 at 11:11 AM
Stifel🏁 $AARD Buy-$24/said: We're initiating coverage of Aardvark with a Buy rating and a $24 target price. Aardvark's ARD-101 represents an under-the-radar, late-stage Prader-Willi (PWS) play with: (1) a unique MOA; (2) a ph2 clinical signal; and (3) a near(ish)-term ph3 readout (3Q26). Now the clinical data and biology are imperfect (par for the course in PWS) and the trial could fail simply by chance (PWS is very challenging). That said, we conducted a deep dive into both the data and biology/mechanism where we're optimistic '101 has a shot-and has a higher POS than shares imply, creating a compelling setup as Vykat validates the PWS opportunity. More specifically—even as we're bullish on Vykat—not everyone will be a candidate/responder: minority share still implies a large opportunity and Vykat's continued success (and any strategic interest it garners) should only benefit '101. Bottom line: it's high-risk/binary, but at a $200MM EV, the risk/reward is heavily upside-biased. $SLNO $RYTM
0 · Reply
Doozio
Doozio Sep. 26 at 9:31 PM
$MLYS HTF as $XBI is now in $RYTM 🐒🍌🧠⏰♾️
0 · Reply
Latest News on RYTM
Rhythm Pharmaceuticals, Inc. - Special Call

Sep 24, 2025, 5:07 PM EDT - 10 days ago

Rhythm Pharmaceuticals, Inc. - Special Call


Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Feb 25, 2025, 11:21 AM EST - 7 months ago

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven


Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Nov 13, 2024, 4:01 PM EST - 11 months ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants


Stonky_Mcprofitface
Stonky_Mcprofitface Oct. 4 at 8:01 AM
$RYTM Bad price?
0 · Reply
TeeMan123
TeeMan123 Oct. 2 at 6:19 PM
$RYTM stock getting pressure over PWS effectiveness… end of day do you trust Meeker sees something or not? Meeker has been super conservative about starting a trial off a whim. You have to give the man the benefit of the doubt.
1 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 12:24 AM
$RYTM: Unusual Options Activity Alerted CALL flow observed 500x contracts at Strike price of $115 Exp on 01/16/2026 with Premium of $265K and showing BEARISH Sentiment
0 · Reply
Quantumup
Quantumup Oct. 1 at 11:52 AM
Stifel⬇️ $SLNO $115 was $118/reit Buy after refreshing its PWS model to reflect recent KOL feedback—still sees pot $2B+ WW rev.. $AARD $RYTM Stifel said: Management remains confident in Vykat's safety and broader risk/benefit profile (i.e., consistent with data/label and known AE-profile), noting feedback from KOLs and patient advocacy groups is positive. Looking ahead, management remains confident in the growth trajectory of Vykat, even as naturally there's some element of a "bolus" here (2Q numbers can't be extrapolated linearly in perpetuity). EU also represents a potential meaningful expansion opportunity next year (similar prevalence numbers; if anything, more concentrated in certain countries). We are also refreshing our PWS market model to reflect our recent KOL feedback (LINK): 50% penetration within the target/addressable population (or 30% of all PWS). This very slightly lowers our estimates but still supports a substantial opportunity ($2B+ WW); our TP goes to $115 (from $118).
0 · Reply
Quantumup
Quantumup Oct. 1 at 10:32 AM
Jones Trading🏁 $AARD Buy/$33 $SLNO $RYTM Jones Trading said: We are initiating coverage of Aardvark Therapeutics (ticker: AARD) with a Buy Rating and $33 PT. Aardvark is a clinical-stage biotech company focused on treating obesity and hyperphagia (excessive eating). The core of Aardvark's portfolio is ARD-101, an oral small molecule agonist of TAS2R, which increases gut-localized secretion of satiety hormones, including GLP-1 and CCK. Jones Trading added:
0 · Reply
abcdzepeda
abcdzepeda Sep. 30 at 6:36 PM
$RYTM Dear Lord , May your favor be with us and allow for some awesome PWS Data to be released soon!  Amen!
0 · Reply
highnihilism
highnihilism Sep. 30 at 7:50 AM
$BUD Anheuser-Busch Inbev: 510 trades, $347K vs $1.08M avg (0.32x). $272K calls / $75K puts. 96% single-leg. $RYTM Rhythm Pharmaceuticals: 17 trades, $275K vs $180K avg (1.52x). $272K calls / $3K puts. 98% single-leg. $UCO ProShares Ultra Bloomberg Crude Oil: 1,063 trades, $440K vs $624K avg (0.70x). $270K calls / $171K puts. 92% single-leg. $NVT Nvent Electric: 196 trades, $311K vs $183K avg (1.70x). $269K calls / $42K puts. 91% single-leg.
0 · Reply
InvestorWisdom
InvestorWisdom Sep. 29 at 2:11 PM
$RYTM nice charts.
0 · Reply
Quantumup
Quantumup Sep. 29 at 11:11 AM
Stifel🏁 $AARD Buy-$24/said: We're initiating coverage of Aardvark with a Buy rating and a $24 target price. Aardvark's ARD-101 represents an under-the-radar, late-stage Prader-Willi (PWS) play with: (1) a unique MOA; (2) a ph2 clinical signal; and (3) a near(ish)-term ph3 readout (3Q26). Now the clinical data and biology are imperfect (par for the course in PWS) and the trial could fail simply by chance (PWS is very challenging). That said, we conducted a deep dive into both the data and biology/mechanism where we're optimistic '101 has a shot-and has a higher POS than shares imply, creating a compelling setup as Vykat validates the PWS opportunity. More specifically—even as we're bullish on Vykat—not everyone will be a candidate/responder: minority share still implies a large opportunity and Vykat's continued success (and any strategic interest it garners) should only benefit '101. Bottom line: it's high-risk/binary, but at a $200MM EV, the risk/reward is heavily upside-biased. $SLNO $RYTM
0 · Reply
Doozio
Doozio Sep. 26 at 9:31 PM
$MLYS HTF as $XBI is now in $RYTM 🐒🍌🧠⏰♾️
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 26 at 12:31 PM
Enter: $RYTM OCT 17 2025 $100 CALLS Buy in Price: $4.30 - $4.50 Take Profit: $7.11 Stop Bleeding: $3.96 ROI Potential: 58% Exit Within: 307 Minutes https://moneygroup.us/alerts
0 · Reply
JarvisFlow
JarvisFlow Sep. 25 at 5:55 PM
Morgan Stanley has updated their rating for Rhythm Pharmaceuticals ( $RYTM ) to Overweight with a price target of 122.
0 · Reply
JarvisFlow
JarvisFlow Sep. 25 at 1:13 PM
JMP Securities has adjusted their stance on Rhythm Pharmaceuticals ( $RYTM ), setting the rating to Market Outperform with a target price of 135 → 142.
0 · Reply
Quantumup
Quantumup Sep. 25 at 10:46 AM
Citizens⬆️the PT on $RYTM to $142 from $135, reit'd Mkt-OP/said it thinks setmelanotide's approval is likely (90% POS) by its PDUFA. Goldman Sachs⬆️ $RYTM's PT to $157 from $138, reiterated at Buy and said, RYTM hosted a Commercial Readiness event which reinforced our positive view on the outlook for setmelanotide in HO ahead of its December 20, 2025 PDUFA; we estimate peak sales of $2.3B in this indication. Goldman Sachs additionally said:
0 · Reply
Quantumup
Quantumup Sep. 24 at 7:57 PM
Morgan Stanley raised the price target on $RYTM to $122 from $109 and reiterated at an Overweight rating. Morgan Stanley said: KOLs excited for approval of setmelanotide due to high unmet need, impressive data and lack of treatment options, and expect rapid uptake in academic centers. Rhythm's initial launch strategy to focus on top volume-based endocrinologists and company to expand sales force in preparation. Due to larger market opportunity than originally projected, we increase HO patient numbers in our model and increase our PT to $122 (from $109); Reiterate OW. $SRRK $SLNO
0 · Reply
anachartanalyst
anachartanalyst Sep. 24 at 6:02 PM
$RYTM https://anachart.com/wp-content/uploads/ana_temp/1758736929_soc-img.jpg
0 · Reply
abcdzepeda
abcdzepeda Sep. 24 at 5:53 PM
$RYTM Any thoughts on why we have been losing momentum? 
1 · Reply
Quantumup
Quantumup Sep. 24 at 11:59 AM
Stifel reiterated $SLNO at Buy-$118 and said, $ACAD announced ACP-101's ph3 trial in Prader-Willi failed. In light of some of the noise around Vykat's safety, $ACAD's readout (even as we think most were skeptical) had become a meaningful overhang for the stock. The setup into these data, in the backdrop of headline risk, questions about potential near-term M&A, etc. we think collectively was a major driver for the pressure on the stock (vs. a complete/fundamental reset on peak sales). As such, this should be a nice clearing event for the stock and allow shares to work again into 3Q EPS where, with a strong print (our expectation), we could see that momentum pre-short report return as the launch progresses (and they potentially expand into EU next year). And while there'll likely be lingering questions still (how durable is this? have safety concerns just not pulled through?), we remain bullish and believe Vykat is well-positioned for significant/sustained growth. $RYTM $BIIB
1 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Sep. 22 at 3:45 PM
$RYTM PDUFA in December. I’m adding on any 5% dips. Will move steadily higher as we approach the date.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 19 at 10:24 PM
Enter: $RYTM OCT 17 2025 $100 CALLS Buy in Price: $3.85 - $6.00 Take Profit: $5.62 Stop Bleeding: $3.39 ROI Potential: 46% Exit Within: 121 Minutes https://moneygroup.us/alerts
0 · Reply
Quantumup
Quantumup Sep. 19 at 12:24 PM
Citizens reiterated $ACAD Market Outperform/$38. Re: PWS data on track to report in 4Q25: sees 20-30%⬆️(55% PoS) on +VE data; 10-15% (45% PoS)⬇️on -VE data. Citizens said in its note to investors: Phase 3 results for ACP-101 in Prader-Willi syndrome (PWS) expected in early 4Q25; we reiterate our Market Outperform rating and risk-adjusted, DCF-derived $38 price target on Acadia Pharmaceuticals. Acadia remains on track to report top-line results in early 4Q25 from the Phase 3 COMPASS-PWS trial evaluating ACP-101 to treat hyperphagia in patients with Prader-Willi syndrome. COMPASS-PWS has been optimized for success, notably through prioritizing the ACP-101 treatment dose that demonstrated efficacy in a previous Phase 3 study (3.2mg TID) and increasing treatment duration from 8 weeks to 12 weeks. We estimate potential upside of 20-30% on positive results (55% probability) and 10-15% downside on negative results (45% probability). $SLNO $AARD $RYTM
0 · Reply
StockConsultant
StockConsultant Sep. 18 at 12:58 PM
$RYTM Rhythm Pharmaceuticals stock watch, pullback to 96.53 support area with high trade quality at https://stockconsultant.com/?RYTM
0 · Reply